Lassogen

Lassogen is developing a new lasso peptide-based therapeutic approach, and we are programming it for the treatment of complex diseases such as cancer and autoimmune disorders. Lasso peptides, naturally produced by bacteria, represent a unique, vast, and untapped source of molecular diversity for drug discovery and development. The distinctive lasso fold and three-dimensional topology of lasso peptides confer these scaffolds with beneficial properties (protease resistance, low pH stability, thermal stability) and potent bioactivities that can target challenging objectives like G-protein-coupled receptors. Lasso peptides also exhibit an increasingly broad range of mechanisms of action, including intracellular enzyme inhibition, extracellular protein binding, biosynthetic intermediate binding, and cell surface receptor modulation. Lassogen possesses a proprietary cutting-edge platform enabling high-throughput production and optimization of our innovative lasso therapeutics. Our founding team has utilized machine learning to develop a genome-mining algorithm that unveils the extreme prevalence of highly diverse lasso peptides across most bacterial phyla.